Autologous MSC-NTF cells ( DrugBank: - )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
2	筋萎縮性側索硬化症	2

2. 筋萎縮性側索硬化症

---

臨床試験数 : 645 /  薬物数 : 589 - (DrugBank : 163) / 標的遺伝子数 : 150 - 標的パスウェイ数 : 225

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04681118 (ClinicalTrials.gov)	March 24, 2021	18/12/2020	Expanded Access Protocol: Repeated Administration of Nurown® (Autologous MSC-NTF Cells) for the Treatment of ALS	Intermediate-size Patient Population Expanded Access Protocol: Repeated Administration of Nurown® (Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors) for the Treatment of Amyotrophic Lateral Sclerosis (ALS)	Amyotrophic Lateral Sclerosis	Biological: NurOwn (MSC-NTF cells)	Brainstorm-Cell Therapeutics	NULL	No longer available	18 Years	63 Years	All			United States
2	NCT02017912 (ClinicalTrials.gov)	May 2014	17/12/2013	Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study of Autologous MSC-NTF Cells in Patients With ALS	A Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study to Evaluate Safety and Efficacy of Transplantation of Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors (MSC-NTF) in Patients With ALS	Amyotrophic Lateral Sclerosis (ALS)	Biological: Autologous MSC-NTF cells;Biological: Placebo	Brainstorm-Cell Therapeutics	NULL	Completed	18 Years	75 Years	All	48	Phase 2	United States